Cargando…

Early Effects of Elexacaftor-Tezacaftor-Ivacaftor Therapy on Magnetic Resonance Imaging in Patients with Cystic Fibrosis and Advanced Lung Disease

This is a prospective, observational study involving three Cystic Fibrosis (CF) adult patients, evaluating the changes in chest magnetic resonance imaging (MRI) three months after the start of elexacaftor/tezacaftor and ivacaftor therapy. MRI showed a drastic reduction in mucus plugging and bronchia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macconi, Letizia, Galici, Valeria, Di Maurizio, Marco, Rossi, Enrica, Taccetti, Giovanni, Terlizzi, Vito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331995/ https://www.ncbi.nlm.nih.gov/pubmed/35893365 http://dx.doi.org/10.3390/jcm11154277

Ejemplares similares

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Concomitant Use of Elexacaftor/Tezacaftor/Ivacaftor and Etanercept in a Cystic Fibrosis Patient with Juvenile Idiopathic Arthritis
por: Orsini, Sara Immacolata, et al.
Publicado: (2023)

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
por: Comegna, Marika, et al.
Publicado: (2021)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022)

ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020)

Elexacaftor–Tezacaftor–Ivacaftor improves exercise capacity in adolescents with cystic fibrosis
por: Causer, Adam J., et al.
Publicado: (2022)

Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis
por: Cavinato, Luca, et al.
Publicado: (2023)

Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease
por: Terlizzi, Vito, et al.
Publicado: (2021)

383: Cystic fibrosis macrophage function after elexacaftor/tezacaftor/ivacaftor initiation
por: Zhang, S., et al.
Publicado: (2021)

THE IMPACT OF TRIKAFTA (ELEXACAFTOR/IVACAFTOR/TEZACAFTOR) ON PATIENTS WITH CYSTIC FIBROSIS WITH COVID-19
por: MILES, B., et al.
Publicado: (2022)

Elexacaftor/Tezacaftor/Ivacaftor Accelerates Wound Repair in Cystic Fibrosis Airway Epithelium
por: Laselva, Onofrio, et al.
Publicado: (2022)

Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome
por: Pallenberg, Sophia T., et al.
Publicado: (2022)

The effect of elexacaftor/tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis
por: Allgood, Sarah, et al.
Publicado: (2023)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
por: Piehler, Linus, et al.
Publicado: (2023)

Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
por: Gramegna, Andrea, et al.
Publicado: (2023)

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study
por: Carnovale, Vincenzo, et al.
Publicado: (2022)

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial
por: Nichols, David P., et al.
Publicado: (2021)

Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy
por: Westhölter, Dirk, et al.
Publicado: (2023)

Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor–Tezacaftor–Ivacaftor
por: Patel, Payal, et al.
Publicado: (2023)

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
por: Kapouni, Nikoletta, et al.
Publicado: (2023)

Triple Therapy for Cystic Fibrosis (Elexacaftor, Tezacaftor, and Ivacaftor): Desensitization After Skin Rash
por: Santos, Ana Isabel, et al.
Publicado: (2023)

Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease
por: Giallongo, Alessandro, et al.
Publicado: (2023)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio)
por: Salehi, Mahan, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
por: Choong, Eva, et al.
Publicado: (2022)

Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis
por: Stekolchik, Elena, et al.
Publicado: (2022)

The Impact of Elexacaftor/Ivacaftor/Tezacaftor on Cystic Fibrosis Patients Who Acquire COVID-19 Infection
por: Miles, Brittany, et al.
Publicado: (2022)

Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy
por: Martin, Christian, et al.
Publicado: (2023)

A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung(✩)
por: Sosinski, Lo M., et al.
Publicado: (2022)

CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy
por: Crow, Hanna, et al.
Publicado: (2022)

Glycemia and β-cell function before and after elexacaftor/tezacaftor/ivacaftor in youth and adults with cystic fibrosis
por: Chan, Christine L., et al.
Publicado: (2022)

Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients
por: Kos, Renate, et al.
Publicado: (2022)

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
por: Bacalhau, Mafalda, et al.
Publicado: (2023)

The Effects of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) on Blood Glucose in Patients With Cystic Fibrosis: A Systematic Review
por: Salazar-Barragan, Marcelo, et al.
Publicado: (2023)

2229. Impact of Elexacaftor/tezacaftor/ivacaftor on Utilization of Antibiotics at a Single Pediatric Cystic Fibrosis Center
por: Elson, Elizabeth C, et al.
Publicado: (2023)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
por: Tümmler, Burkhard
Publicado: (2023)

Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation
por: Roder, Lauren, et al.
Publicado: (2022)

LBODP085 Effects Of Elexacaftor-tezacaftor-ivacaftor On Glucose Tolerance And Other Metabolic Parameters In Children With Cystic Fibrosis
por: Choudhari, Pooja, et al.
Publicado: (2022)

Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy
por: Stanke, Frauke, et al.
Publicado: (2023)

Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study
por: Fila, Libor, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sl8bfb8q7ctr04p78dffrv1fuv